Vistin Pharma ASA (LTS:0RAM) Earnings per Share (Diluted): kr1.68 (TTM As of Mar. 2026)


LTS:0RAM Vistin Pharma ASA LTS:0RAM
77 GF Score
Price kr20.30
GF Value kr25.69
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Vistin Pharma ASA Earnings per Share (Diluted)?

Vistin Pharma ASA LTS:0RAM 77 Earnings per Share (Diluted) is kr1.68 as of Mar. 2026. GuruFocus rates LTS:0RAM with a GF Score™ of 77/100 and a GF Value™ of kr25.69 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 786 Drug Manufacturers companies, Vistin Pharma ASA ranks worse than 127226.34% on this metric.

Vistin Pharma ASA's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was kr0.48. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr1.68.

Vistin Pharma ASA's EPS (Basic) for the three months ended in Mar. 2026 was kr0.48. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was kr1.68.

Vistin Pharma ASA's EPS without NRI for the three months ended in Mar. 2026 was kr0.48. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was kr1.70.

During the past 12 months, Vistin Pharma ASA's average EPS without NRIGrowth Rate was 2.60% per year.

During the past 13 years, Vistin Pharma ASA's highest 3-Year average EPS without NRI Growth Rate was 38.00% per year. The lowest was -25.70% per year. And the median was 14.65% per year.


Vistin Pharma ASA  (LTS:0RAM) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Vistin Pharma ASA Earnings per Share (Diluted) Related Terms


Vistin Pharma ASA Earnings per Share (Diluted) Historical Data

* Premium members only.

The historical data trend for Vistin Pharma ASA's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistin Pharma ASA Earnings per Share (Diluted) Chart

Vistin Pharma ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 -0.11 1.03 1.42 1.69

Vistin Pharma ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.42 0.42 0.36 0.48

LTS:0RAM vs ZTS, UTHR, VTRS: Earnings per Share (Diluted) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vistin Pharma ASA PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's PE Ratio distribution charts can be found below:

* The bar in red indicates where Vistin Pharma ASA's PE Ratio falls into.


LTS:0RAM
77GF Score
Vistin Pharma ASA LTS:0RAM
Earnings per Share (Diluted) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistin Pharma ASA Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Vistin Pharma ASA's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as

Diluted Earnings Per Share (A: Dec. 2025 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(74.751-0)/44.345
=1.69

Vistin Pharma ASA's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2026 is calculated as

Diluted Earnings Per Share (Q: Mar. 2026 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(21.491-0)/44.435
=0.48

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

What does a Earnings per Share (Diluted) of kr1.68 mean?
Vistin Pharma ASA (LTS:0RAM) has a Earnings per Share (Diluted) of kr1.68 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Vistin Pharma ASA and its competitors. According to the industry distribution chart, Vistin Pharma ASA ranks #999999 out of 786 companies in the Drug Manufacturers industry.
Is Vistin Pharma ASA's Earnings per Share (Diluted) too high?
Vistin Pharma ASA's current Earnings per Share (Diluted) is kr1.68. Based on the distribution chart, Vistin Pharma ASA ranks #999999 out of 786 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Earnings per Share (Diluted) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #999999 out of 786 companies for Earnings per Share (Diluted). This places Vistin Pharma ASA in the lower half of its industry. The industry median Earnings per Share (Diluted) is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.60, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Earnings per Share (Diluted) is kr1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.69, compared to a current price of kr20.30 — trading 21% below its estimated fair value. The current Earnings per Share (Diluted) is kr1.68. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Earnings per Share (Diluted) is kr1.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?

Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued. The current stock price of kr20.30 is trading 21% below its estimated GF Value™ of kr25.69. GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.

Key valuation signals for LTS:0RAM:

  • Earnings per Share (Diluted): kr1.68
  • GF Value™: kr25.69 vs. price of kr20.30 (21% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vistin Pharma ASA Business Description

Address Ostensjoveien 27, P.O. Box 6735 Etterstad, Oslo, NOR, 0661
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score

Get the complete analysis for LTS:0RAM

Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr20.30
Price
kr25.69
GF Value